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Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with
several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and
an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change.
In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our
knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will
describe the major areas of clinical research that will report over the next few years.
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The treatment of metastatic clear cell renal carcinoma (RCC)
has dramatically changed over the last 5 years. This has been
driven by two groups of targeted agents; namely vascular
endothelial growth factor (VEGF)-targeted therapies and mamma-
lian target of rapamycin (mTOR) inhibitors. Both, first and
second line treatment is of proven benefit and these agents have
replaced immune therapies that were previously standard of care
for metastatic RCC (Motzer and Bukowski, 2006; Motzer et al,
2009).
Sunitinib is a multitargeted tyrosine kinase inhibitor (TKI)
that predominantly targets VEGF (Figure 1). It also has ‘off target’
effects, involving other tyrosine kinases that may account for
some of its activity and toxicity (Motzer and Bukowski, 2006).
The pivotal trial of sunitinib was published in 2006; and
subsequently it has established itself as standard first line therapy
(Motzer et al, 2009). The exact mechanism of its activity in RCC
remains unknown, and it is not yet possible to identify specific
cohorts of patients who benefit from therapy. Additionally,
sunitinib and the other drugs are only effective in controlling the
disease for a limited period before progression occurs. There-
fore, an important area of research is investigating mechanisms of
resistance.
Sunitinib is one of a number of VEGF-targeted agents with
activity in this setting. Four drugs including sunitinib have been
approved by the FDA for the treatment of metastatic RCC. The
other three agents are sorafenib, pazopanib and bevacizumab
(Escudier et al, 2007a,b; Rini et al, 2008a,b; Sternberg et al, 2009).
Newer agents under investigation in ongoing randomised trials
include tivozinib, dovitinib and axtitinib. It is hoped that these
agents will show improved activity, decreased toxicity or set a
benchmark as second or third line therapy. However, none of these
trials are aimed at specific subsets of patients with metastatic clear
cell RCC.
The other major group of targeted agents in renal cancer is
the mTOR inhibitors. These include temsirolimus and everolimus
that are both widely used and have proven activity (Hudes
et al, 2007; Motzer et al, 2008a,b). Once again there has been
a failure to identify specific groups of patients that benefit from
these agents, and although these agents offer initial benefit,
resistance occurs.
This review addresses our current understanding of the role of
targeted therapy in renal cancer. It will also highlight areas in
which our understanding is incomplete and finally will describe
the major areas of clinical research, which will report over the next
few years.
HISTOLOGY AND PROGNOSIS IN METASTATIC
RENAL CANCER
Renal cell carcinoma consists of a number of histological subtypes,
the most common of which is clear cell RCC. It is characterised by
a mutation to the Von Hippel Lindau protein that is linked to both
regulation of HIF and VEGF (Na et al, 2003) (Figure 1). Papillary
RCC accounts for the bulk of the remaining ‘non-clear cell’
tumours. The majority of trials focus on the clear cell population
in which HIF/VEGF appears to be the dominant tumour biology
(Rini et al, 2008a,b).
The most commonly used method for predicting outcome of
patients with metastatic renal cancer is the Memorial Sloan-
Kettering Prognostic score. It stratifies patients into three groups
(good, intermediate and poor) depending on a number of factors,
including lactate dehydrogenase, performance status, serum
calcium, haemoglobin and time since diagnosis to treatment
(Motzer and Bukowski, 2006). Although designed before the
introduction of targeted therapy it has been validated in the TKI
era (Motzer et al, 2008; Heng et al, 2009).
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www.bjcancer.comSUNITINIB IN METASTATIC RENAL CANCER
Sunitinib is superior to interferon in the first line treatment of
clear cell RCC. In the pivotal study the progression-free survival
(PFS) was 11 months for sunitinib vs 5 months for interferon
(hazard ratio (HR): 0.53; (95% CI: 0.45–0.64); Po0.001) (Motzer
et al, 2007, 2009). Most of the study patients were MSKCC good
and intermediate risk, had a good performance status and a
nephrectomy before treatment. The majority of patients on the
interferon arm subsequently received sunitinib (33%) or other
VEGF-signalling inhibitors (32%) confounding the overall survival
(OS) data (26.4 months for sunitinib vs 21.8 months for interferon
(HR: 0.821; 95% CI: 0.673–1.001; P¼0.051). Subsequent analysis
of those patients who did not cross over to sunitinib showed an
OS of 14 months for interferon and 28 months for sunitinib
(Flanigan et al, 2001; Motzer et al, 2009). The benefits of sunitinib
were present in all three MSKCC prognostic groups, although the
numbers in the poor-risk category were small (o10% of the study
population) resulting in statistically insignificant data. Subsequent
data from a large expanded access series reproduced the PFS
results (10.9 months; 95% CI: 10.3–11.2 months), with an OS of
18.4 months (95%CI: 17.4–19.2 months) underlining the practise
changing nature of these results (Gore et al, 2009).
There is a lack of randomised data for sunitinib in the non-clear
cell population. The most comprehensive data comes from the
expanded access cohort in which the PFS and OS were 7.8 (95% CI:
6.3–8.3) months and 13.4 (95% CI: 10.7–14.9) months, respec-
tively (Gore et al, 2009). A further retrospective analysis supported
the use of sunitinib in this setting with a PFS of 11.9 months
(Choueiri et al, 2008).
The most common toxicities encountered with sunitinib
included (grade 3 or more) hypertension (12%), fatigue (11%),
diarrhoea (9%) and hand–foot syndrome (9%). In the landmark
phase III study 50% of the patients required a dose reduction of
sunitinib due to these events (Motzer et al, 2008a,b). A recent
meta-analysis identified a relationship between steady-state area
under the curve of sunitinib and time to tumour progression,
toxicity and OS (Houk et al, 2009) suggesting increased exposure
to sunitinib appears to be associated with improved clinical
outcomes, as well as increased risk of adverse effects. Therefore,
attempts should initially be made to address toxicity before dose
reductions are made. Sunitinib is currently given at 50mg for
4 consecutive weeks followed by a 2-week treatment-free interval.
Phase II data investigating continuous dosing at 37.5mg showed
similar toxicity profile to the 50mg intermittent dose (Escudier
et al, 2009a,b,c). A randomized phase II study comparing the
standard 50mg regimen with continuous 37.5mg dosing is
exploring this regimen formally and will report in 2010.
PREDICTING CLINICAL BENEFIT WITH TARGETED
THERAPY
A number of prognostic biomarkers have been identified that
correlate with a poor outcome with sunitinib. These include the
MSKCC prognostic criteria, raised platelet/neutrophil levels at
diagnosis (Heng et al, 2009; Motzer et al, 2008a,b). However, it has
not been possible to identify biomarkers or imaging modalities
that predict clinical benefit with specific agents. Sunitinib causes
dynamic changes to cytokine expression and growth factors;
however, it remains unclear whether these predict clinical benefit
(Rini et al, 2008a,b). Further work in this area is required.
Although widely used, response rates using CT (RECIST criteria)
do not correlate with outcome (Kontovinis et al, 2009). Other
methods of correlating CT changes with outcome, such as the Choi
criteria, which measures tumour attenuation (Hounsfield units), as
well as changes in two-dimensional size, are under investigation
and hold promise (van der Veldt et al, 2010). Other imagining
modalities, such as dynamic contrast enhanced MRI and FDG-
PET, are also being investigated (Hahn et al, 2008).
Perhaps the most promising current biomarker is the presence
of treatment-associated hypertension, which in retrospective
analysis, appears to correlate with outcome (Rixe et al, 2008).
This finding is under investigation in prospective studies with
axitinib. It raises a number of issues, for example, is this finding a
pharmacokinetic or pharmacodynamic affect and if the hyperten-
sion is associated with clinical benefit how aggressively should it
be managed?
The optimal way of identifying predictive rather than prognostic
biomarkers in this setting is with prospective studies comparing
VEGF-targeted agents with other classes of drug, such as the
mTOR inhibitors. Using this approach it is possible to determine
whether subgroups benefit from the specific agents rather than just
identifying prognostic markers. Clinical trials such as RECORD 3
that compares sunitinib and everolimus are the closest we have to
this design, although the identification of biomarkers in not the
primary endpoint and the translational component is, therefore,
not comprehensive.
OTHER VEGF-TARGETED AGENTS
(Table 1) Sorafenib and bevacizumab were both developed at
approximately the same time as sunitinib in RCC. Sorafenib is
associates with a PFS benefit as second line therapy after interferon
failure (Escudier et al, 2007a,b). However, a first line sorafenib vs
interferon randomised phase II study showed no benefit for
sorafenib, making it less attractive in this setting (Escudier et al,
2009a,b,c).
Two randomised phase III studies investigated bevacizumab in
combination with interferon vs interferon alone as first line
treatment for metastatic RCC (Escudier et al, 2007a,b; Rini et al,
2008a,b). These studies focused on the clear cell population and
consisted of predominantly good and intermediate risk patients.
Both studies showed a benefit for the combination in terms of PFS
(5.1 vs 8.5; 5.4 vs 10.2), with the OS for in the bevacizumab arm of
18.3 and 22.9 months ref.
More recently Pazopanib has received FDA and EMA approval.
In the pivotal randomised phase III study the PFS for the



























Figure 1 Diagrammatic representation of the mechanism of action of
targeted therapy in clear cell renal cancer. This figure shows how HIF-1 is
unregulated within the clear cell renal cancer tumour cell by two
mechanisms. This upregulation in turn stimulates receptors on endothelial
cells (VEGF and PDGF). Dotted lines denote the drug targets. Off-target
effects on the stroma and tumour cells are not represented.
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Po0.001) (Sternberg et al, 2009). The toxicity profile for
pazopanib may be different to the other VEGF TKIs with the
most common adverse event being diarrhoea (52%; 4% Grade 3 or
4), hypertension (40%; 4% Grade 3 or 4), hair colour changes
(38%) and nausea (26%; o1% Grade 3 or 4). The incidence
of fatigue and ‘hand and foot syndrome’ appears to be relatively
low (grade 3 or more in 5 and 2%, respectively). However,
abnormalities in liver function tests (43  normal) occurred in
20% of patients (Sternberg et al, 2009; Hutson et al, 2010). These
factors may help select the optimal agent for individuals. A pivotal
study comparing pazopanib and sunitinib in the first line setting
has closed recruitment and will report in 2011.
Although direct comparison of the above agents is not currently
possible because of the lack of direct randomized studies in the
first line setting, indirect comparison is possible but flawed in
nature (Table 1). Nevertheless sunitinib has set a benchmark for
both overall and PFS here, although the PFS for pazopanib is also
11 month and is, therefore, promising. In view of the fact that
sorafenib did not appear superior to interferon it is more difficult
to recommend this agent above those with proven superiority to
interferon, such as bevacizumab (with interferon) and sunitinib
(Escudier et al, 2009a,b,c).
mTOR INHIBITORS
Everolimus and temsirolimus are both mTOR inhibitors (TORC1)
that have been investigated and are widely used in metastatic RCC
(Hudes et al, 2007; Motzer et al, 2009) (Figure 1). Temsirolimus
was investigated in untreated poor risk disease. Results of this
study showed prolonged OS for temsirolimus compared with
interferon (HR for death: 0.73; 95% CI: 0.58–0.92; P¼0.01).
However, the combination of temsirolimus and interferon together
did not show significant benefit over temsirolimus alone. It is
speculated that this may be because of the dose intensity achieved
in this arm of the study. Subset analysis showed significant benefit
for non-clear cell population that is of particular interest and
warrants further investigation. The drug was relatively well
tolerated with fewer serious adverse events in the temsirolimus
group than in the interferon group (P¼0.02).
Everolimus is the only agent with positive randomised data after
TKI failure in RCC (Motzer et al, 2009). RECORD 1 compared the
effects of everolimus and placebo in patients who had previously
received at least one line of targeted therapy. The PFS strongly
favoured everolimus (HR: 0.30; 95% CI: 0.22–0.40; Po0.0001).
Perhaps, the most significant toxicity seen was pneumonitis (any
grade 8%), which requires particular attention with using this
agent.
VEGF INHIBITORS AS SECOND LINE THERAPY
IN RCC
Although phase III data support the use of sorafenib as second line
therapy, this study conducted in the era of immune therapy and
(Escudier et al, 2007a,b), there is no randomised data to support
further VEGF TKI therapy after failure of initial targeted therapy.
However, phase II data suggest that there may be non-cross
resistance between these agents (Rini et al, 2009; Sablin et al,
2009). Therefore, the use of sequential VEGF-targeted therapy
may be beneficial. A number of randomised phase II and III
studies, which investigate a switch from one TKI to another,
are ongoing. Pazopanib, sorafenib, axitinib, cediranib and
sunitinib are all being investigated in this setting. Data with
axitinib is likely to be the first of these studies to report. Axitinib is
a potent VEGF-specific target TKI with few ‘off target’ effects.
Results in the post interferon setting are impressive (PFS of 15.7
months (95% CI: 8.4–23.4)) and a phase II study that investigated
axitinib post sorafenib are particularly striking (PFS and OS
were 7.4 months (95% CI: 6.7–11.0) and 13.6 months (95% CI:
8.4–18.8), respectively) (Rixe et al, 2007; Rini et al, 2009).
A randomised phase III second line study, comparing sorafenib
and axitinib post VEGF-targeted therapy is now closed and results
are awaited. The occurrence of hypertension with axitinib may
predict clinical benefit, which is being investigated formally in
clinical trials (Rixe et al, 2008).
OTHER AGENTS UNDER INVESTIGATION
Tivozinib is a potent VEGF TKI with impressive clinical data. In
a randomised discontinuation study 88% of patients obtained a
clinical benefit from the drug (Bhargava et al, 2009). A randomised
phase III study comparing tivozinib and sorafenib in patients not
previously exposed to targeted therapy will close in December
2010. Dovitinib is another promising TKI that targets FGF-2, as
well as VEGF. It is being investigated in the third line setting in
mTOR refractory disease.
COMBINATION THERAPY
A logical step in improving outcomes is to investigate these
drugs in combination. However, combining sunitinib with other
forms of targeted therapy has been difficult because of excessive
toxicity (Feldman et al, 2009). This may not be the case with
bevacizumab, which has been shown to be tolerable in combina-
tion with other agents such as everolimus. In a phase II study of
bevacizumab and everolimus the median PFS for this combination
was 9.1 months with response rates of 30% (Hainsworth et al,
2010). A recent randomised phase II study comparing sunitinib
v.s. bevacizumab and interferon v.s bevacizumab and temsirolimus
demonstrated significant toxicity for the latter combination
without any efficacy advantage (Escudier et al, 2010). Perhaps,
the most early awaited combination data is RECORD II that
compares bevacizumab and everolimus vs bevacizumab and
interferon. The potential disadvantages of combination therapy
include additional toxicity, cost and the theoretical risk of
multidrug resistance. Early results in this setting have been
disappointing.












Motzer et al, 2007 Clear cell All Sunitinib vs interferon 11 vs 5 26.4 vs 21.8
Hudes et al, 2007 All types Poor Temsirolimus vs interferon 5.5 vs 3.1 10.9 vs 7.3
Escudier et al, 2007a,b Clear cell All Bevacizumab + interferon vs interferon 10.2 vs 5.4 22.9 vs 20.6
Rini et al, 2008a,b Clear cell All Bevacizumab +interferon vs interferon 8.5 vs 5.1 18.3 vs 17.4
Sternberg et al, 2009 Clear cell All Pazopanib vs placebo 11.1 vs 2.8 NA
aThe first figure is that of the study arm the second figure is for the control arm.
Targeted therapy in renal cancer
T Powles et al
743
British Journal of Cancer (2011) 104(5), 741–745 & 2011 Cancer Research UKMECHANISMS OF RESISTANCE TO THERAPY
The mutation to the VHL gene and subsequent activation of HIF
and VEGF are hall marks of clear cell renal cancer. The VEGF-
targeted therapy is thought to work by blocking the angiogenic
effects of this overactive pathway (Gossage and Eisen, 2010). Only
a small minority of renal tumours initially progress through VEGF-
targeted therapy, and the majority of patients initially obtain
clinical benefit with these drugs (Motzer et al, 2009). However,
resistance occurs, which is usually referred to as acquired
resistance (Rini and Atkins, 2009). The onset of this acquired
resistance is variable both in terms of time and clinical pattern,
and our understanding of it at the molecular level is in its infancy.
This is largely due to the lack of sequential tissue for comparative
analysis.
Unlike in other malignancies, the acquisition of specific
mutation to the target of the drug is not thought to be responsible
for resistance in RCC (Valent, 2008; Rini et al, 2009). This is
because in RCC the main target for sunitinib is the VEGF receptors
on the vascular endothelium that are genetically stable.
There are currently two main theories to account for acquired
resistance. First, it is speculated that ‘angiogenic escape’
occurs, in which with time the initial targeted therapy becomes
ineffective at blocking the VEGF axis. This hypothesis is supported
by the observation that switching from one VEGF-targeted therapy
to another potentially more potent agent results in further
responses (Rini et al, 2009). It is speculated that this may be
due to upregulation of associated growth factors, such as
HIF1-a (Rini et al, 2009). The second area of investigation is
based around the emerging preclinical data that support the role of
alternative pathways and growth factors in propagating tumour
growth in acquired resistance. Specifically, FGF-2, tie2/Ang2, il-8
and the Src family have been implicated in this process (Oliner
et al, 2004; Cenni et al, 2005; Bergers and Hanahan 2008).
Clinical trials have been designed to target all these protein with
dovotinib, AMG386 and saracatinib. Resistance also occurs
universally with the mTOR inhibitors. The current drugs in mRCC
only target TORC1 and it appears that inhibition of this in
isolation leads to compensatory upregulation of PI3 kinase
(O’Reilly et al, 2006). The development of combined TORC1
and 2 inhibitors could potentially overcome this and will be
investigated in mRCC (Sarbassov et al, 2006).
CLINICAL TRIALS IN THE FUTURE
The two main goals over the next 5–10 years in mRCC are to firmly
establish the most effective agents in each class and identify
predictive biomarkers associated with clinical benefit to specific
agents. To achieve these goals two different trial designs are required.
Randomised phase III studies comparing newer agents with bench-
mark controls (currently sunitinib for the first line and everolimus
for second line) are required to redefine standard therapy. The
COMPARZ study, a non-inferiority study, which compares pazopa-
nib and sunitinib, has just closed and is due to report in 2011/12.
Results are eagerly awaited by further studies with tivozinib and
axitinib vs a benchmark are required before there is clarity about the
optimal first line VEGF TKI. The assumption that these agents are
more active in the first-line setting without the appropriate studies is
flawed, despite their impressive efficacies in other settings. Sorafenib
should not be considered an adequate benchmark control in the first
line setting (Escudier et al, 2009a,b,c).
There is also a need for smaller biomarker studies, which take
sequential tissue, plasma and functional imaging during therapy.
These studies are aimed at gaining a better understanding of how
each drug works. The true goal for these studies is to identify
predictive biomarkers for specific agents, which requires rando-
misation against other agents.
CONCLUSIONS
Targeted therapy has changed the way metastatic renal cancer is
treated and the OS for these patients is now greater than 2 years in
prospective studies. Sequential therapy with VEGF-targeted
therapy and mTOR inhibitors are currently the standard of care.
Data on specific combinations are eagerly awaited. Correlative
markers associated with clinical benefit remain elusive and are
urgently required to develop treatment for this disease. This will
help us to move away from the current ‘one size fits all’ approach
and help develop truly individualised targeted therapy.
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